<DOC>
	<DOCNO>NCT00687258</DOCNO>
	<brief_summary>The main purpose longitudinal study point effect VitabranE ESA resistance anemia observe HD patient undergo EPO maintenance therapy . As secondary purpose consider effect VitabranE inflammation oxidative stress parameter function change observe anemia parameter .</brief_summary>
	<brief_title>Evaluation Of A New Vitamin E-Bonded Membrane On Anemia And Oxidative Stress In End-Stage Renal Disease Patients</brief_title>
	<detailed_description>Aim The aim pilot randomize study verify whether addition vitamin E alpha-tocopherol blood-side layer synthetic polysulfone dialyser membrane clinical advantage term ESA responsiveness , consequently , anemic status hemodialysed patient . Patients Patients gender age 18 year consider eligible study receive bicarbonate hemodialysis treatment least six month stable ESA therapy least three month , adequate iron store ( ferritin level &gt; 200 ng/ml transferrin saturation &gt; 20 % ) . Patients haemoglobinopathy , sickle cell anemia , thalassemia malignancy exclude , experienced infection , vascular access thrombosis , stroke , myocardial infarction , heavy blood loss , major surgery blood transfusion previous three month . Study design This 8-month , control randomise study two parallel group ; give informed consent , enrol patient randomly assign Vi-E experimental treatment ( polysulfone dialyser vitamin E alpha-tocopherol ) PS control treatment ( polysulfone dialyser without vitamin E alpha-tocopherol ) . Clinical data The dialyser randomly assign begin study , pre end-dialysis body weight , blood pressure heart rate record baseline every two month . Dialysis prescription change study . All drug administer dialysis session record , prescribe inter-dialysis therapy . Laboratory data Hemoglobin , serum albumin plasma high-sensitivity C reactive protein level ( ELISA ) record baseline every month , together nutritional inflammation index . Iron status evaluate basis transferrin saturation plasma ferritin level . Reticulocytes PTH level also record . Equilibrated Kt/V calculate order estimate dialysis dose low molecular weight uraemic toxin , appearance urea nitrogen calculate order estimate daily protein intake . Plasma alpha-tocopherol gamma tocopherol level determine mean reverse-phase HPLC analysis ; total antioxidant capacity ( TAC ) determine use ferric reducing-antioxidant power advance glycation end-products detect use total fluorescence 335/385 Ex/Em . Advanced oxidation protein product , carbonyl product , erythrocyte creatine interleukin 6 also determine . Main response variable The primary outcome measure ESA resistance index , combine variable calculated divide weekly ESA dose haemoglobin level end-dialysis body weight . Sample size Given pilot nature study , estimate sample twenty patient ( ten patient per group ) sufficient provide reasonable control random variation ESA resistance . Statistical analysis The data describe use median value interquartile range base 25th 75th percentile distribute continuous variable . The baseline distribution continuous categorical variable group investigate use Mann-Whitney Chi-squared test appropriate . The follow-up data analyze use analysis variance repeat measure order test possible difference ESA resistance time two group . A secondary analysis make add value baseline covariates order identify predictor associate ESA resistance . In order reduce over-parameterizing model , explore covariates group two hierarchical step : 1 . Biocompatibility previous membrane ( categorical ) , iron status ( transferrin saturation ferritin ) , nutrition ( albumin ) , intact PTH , inflammation ( high- sensitivity C reactive protein ) ; 2 . Add marker oxidative stress ( TAC , alpha- gamma-TOC , carbonyl product , AOPP , AGEs erythrocyte creatine ) The effect experimental treatment time test mean group interaction , hierarchical approach .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<criteria>1 . Male female patient , age â‰¥ 18 , stabilize BHD least 6 month . 2 . Clinical stability last 3 month . 3 . Serum Ferritin &gt; 200 mg/L Transferrin saturation &gt; 30 % . 4 . Maintenance therapy epoetin alfa/beta darbepoetin alfa . 1 . One follow condition last 3 month : acute infection vascular access thrombosis ictus cerebri myocardial stroke haemorrhage major surgery haemotransfusion 2 . Haemoglobinopaty , sickle cell anemia , familial erythroblastic anemia haematological disorder interfere aim study 3 . Malignancy 4 . Participation study use EPO analogue yet commercialize 5. pharmacological dosage administration antioxidant supplement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Oxidative Stress</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>dialyser membrane</keyword>
	<keyword>Vitamin E</keyword>
	<keyword>Erythropoietin responsiveness</keyword>
	<keyword>Erythropoietin resistance</keyword>
	<keyword>hemodialysis</keyword>
</DOC>